Mina Mar Marketing – Blog & Announcements

TORONTO, Feb 09, 2010 /PRNewswire via COMTEX/ — Hard to Treat Diseases (HTDS; www.htdsmedical.com), continuing on the company’s announcement from the January 22, 2010, where the company announced a targeted merger with a medical company from Middle East, HTDS is using this opportunity to inform the public that as the merger negotiations progress at a good pace. The company amended its share structure to accommodate the merger.

HTDS increased the number of its authorized shares to 8.8 billion to accommodate the merger and the size of the new medical company from middle east/Israel, and expand the Melem Secrets cosmetics line. HTDS will publish full details about the new company as soon as both sides finalize the merger. Filings from Florida State are filed with Pink Sheets. Obviously if the merger does not happen the stock will be returned to the treasury of HTDS.

The new merger candidate operates an obstetrician type medical company. This Middle Eastern company focuses on treatment of pre-term labor and induction of labor. The company seeks cooperation with HTDS to co-develop this enzyme and meet GMP and FDA enzyme/cytokines production; as well as to develop Phase II clinical trials in China and share production and marketing with HTDS.

Pre-term birth affects 11 percent of births in the USA each year, and accounts for 75% of infant deaths and 50% of the long-term neurological handicaps, including cerebral palsy, blindness, deafness, and developmental defects. The direct care in Neonatal Intensive Care Units (NICU) costs staggering $45 billion to $65 billion in the developed world, treating an estimated 1.5 million pre-term infants, with total of about 4.5 million NICU hospitalization weeks.

To be included in HTDS’ email database for press releases and industry updates, please subscribe at or opt in with your email address at this link: http://www.minamargroup.com/updates/.

WUHAN, China, Feb 09, 2010 /PRNewswire via COMTEX/ — Landstar Inc.’s (LDSR; http://www.landstarcorp.com) subsidiary Hubei Chuguan Industrial Co., Ltd. met with the representatives of the Municipal Government of the Foshan City, Guangdong Province, to discuss the use of Hubei Chuguan technology across Foshan City.

Hubei Chuguan Director and the marketing team met with the Mayor of Foshan City to discuss possible cooperation between the Hubei Chuguan and Foshan City. The company presented its plan to the Mayor of Foshan and carried out a detailed discussion on the economic and ecological benefits of this oil and gas recovery technology for the city. The parties also discussed detailed cooperation issues of a possible contract. The Hubei Chuguan Director submitted a proposal for installation of Hubei Chuguan oil and recovery technology and infrastructure upgrades for the city, and the parties agreed to continue this dialogue in the near future.

Mr. Lee, the Director of Hubei Chuguan said, “Our talks with the Foshan Mayor went well and there is a great will for cooperation. We offer people outstanding opportunity to save money and save the planet one drop of oil at the time. Things are happening for Landstar Inc. and we are marching forward, because the opportunities for our technology in China are endless.”

Hubei Chuguan Industry Co. Ltd., a subsidiary of LandStar Inc., provides recycling solutions on settlement and reconstruction for oil and gas. With the technologies of Nippon Oil Corporation at its core, Hubei Chuguan Industry Co. Ltd. purchases parts and assembles these recycling units in China.

In other updates, as previously announced discussions for a four way merger with two separate China based companies is progressing rather well. Our representatives held a very productive and lengthy discussion with a USA Georgia State energy company. While the USA company is reviewing the proposal put forth by LDSR, LDSR management is also looking at various options available to either take the entire Georgia project under its wing or as a majority stakeholder. Mr. Lee, the Director of Hubei Chuguan and CEO of LDSR concluded “It appears that all four entities’ minds and heart are in this mega merger. Now the focus is on the logistics and operational matters and what LDSR will look like after this is all complete. As a company we remain committed to keep our followers advised and we intend to do so via news or Pink Sheets filings as soon as any material or substantial update becomes available.”

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates

BEIJING, Feb 08, 2010 /PRNewswire via COMTEX/ — Hiru Corporation (PINKSHEETS: HIRU) (www.hirucorporation.com) and its subsidiary Jiangxi RongYu Pharmaceutical Group, Inc. (www.jxrongyuyy.com) announce that one of the company’s products has been officially added onto the National Essential Drugs List.

Jiangxi Leading Group Office issued an ordinance of qualified candidates for the ‘National Essential Drug List’; and Jiangxi RongYu product, the ‘Yuan Hu Zhi Tong Capsule’ had been added to this List. As by the decree of the Ministries of Finance and of Health, all medicines placed on this list must be available to doctors and in stock with pharmacies and county hospitals. The government health plan also fully covers and reimburses the patients for the use of this medicine.

Being placed on this list and the fact that the medical authorities are required by law to carry this medicine increases Jiangxi RongYu Pharmaceutical Group’s sales and marketing efficiency, while significantly reducing marketing and distribution costs for this product.

‘Yuan Hu Zhi Tong Capsule’ or ‘Yuan Hu Zhi Tong Pian’ is a traditional formula for alleviating pain, including headaches, menstrual discomfort, liver or gallbladder problems, angina and muscle spasms.

In other company events, the company has today filed its up to date Adequate Disclosure with Pink Sheets. Also in addition to the Adequate Disclosure the company has also filed certain industry research reports with The Pink Sheets for the company followers review.

Hiru Corporation is a parent company of China based pharmaceutical company – Jiangxi RongYu Pharmaceutical Group, Inc. Hiru opens its way to become a multinational player with substantial operations and revenues. Jiangxi RongYu Pharmaceutical Group, Inc. (http://www.jxrongyuyy.com/) is strong and strategically-balanced Pharmaceutical Co with plans to enter international trade markets, expand and deliver the expanding product lines worldwide.

To be included in HIRU’s email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.